Wide Ranks

CMPX

Compass Therapeutics, Inc.

1.56

Top Statistics
Market Cap 214 M Forward PE -3.77 Revenue Growth 0.00 %
Current Ratio 31.84 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.57 Enterprise / Revenue 101.31 Price To Sales Trailing12 Months 252.52
Profitability
Profit Margins 0.00 % Operating Margins -6522.82 %
Balance Sheet
Total Cash 135 M Total Cash Per Share 0.9840 Total Debt 6 M
Total Debt To Equity 4.97 Current Ratio 31.84 Book Value Per Share 1.01
All Measures
Short Ratio 223.00 % Message Board Id finmb_266166780 Shares Short Prior Month 2 M
Return On Equity -0.3200 City Boston Uuid 2da7fead-7fe9-351a-a396-4dd759234d3a
Previous Close 1.51 First Trade Date Epoch Utc 1 B Book Value 1.01
Beta 0.7460 Total Debt 6 M Volume 679638
Price To Book 1.55 Fifty Two Week Low 0.7650 Total Cash Per Share 0.9840
Total Revenue 850000 Shares Short Previous Month Date 1 B Target Median Price 8.00
Max Age 86400 Recommendation Mean 1.57 Sand P52 Week Change 0.3133
Operating Margins -6522.82 % Target Mean Price 8.00 Net Income To Common -47757000
Short Percent Of Float 0.0126 Implied Shares Outstanding 137 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 601790 Average Volume10days 601790
Total Cash 135 M Next Fiscal Year End 1 B Revenue Per Share 0.0060
Held Percent Insiders 0.1204 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.51 Target Low Price 4.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.73 Open 1.54
Free Cashflow -31852500 State MA Dividend Yield 0.00 %
Return On Assets -0.2171 Time Zone Short Name EST Trailing Eps -0.3500
Day Low 1.52 Address1 80 Guest Street Shares Outstanding 137 M
Price Hint 4 Target High Price 10.00 Website https://www.compasstherapeutics.com
52 Week Change -0.0545 Average Volume 510298 Forward Eps -0.5100
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 3054.40 %
Is_sp_500 False Regular Market Day High 1.64 Profit Margins 0.00 %
Debt To Equity 4.97 Fifty Two Week High 2.34 Day High 1.64
Shares Short 1 M Regular Market Open 1.54 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 101.31 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0089 Operating Cashflow -48047000 Currency USD
Time Zone Full Name America/New_York Market Cap 214 M Is_nasdaq_100 False
Zip 02135 Quote Type EQUITY Industry Biotechnology
Long Name Compass Therapeutics, Inc. Regular Market Day Low 1.52 Held Percent Institutions 0.6919
Current Price 1.56 Address2 Suite 601 Enterprise To Ebitda -1.57
Financial Currency USD Current Ratio 31.84 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country United States
Float Shares 88 M Two Hundred Day Average 1.52 Enterprise Value 86 M
Price To Sales Trailing12 Months 252.52 Forward PE -3.77 Regular Market Volume 679638
Ebitda -54834000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.

The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies.

The company was founded in 2014 and is headquartered in Boston, Massachusetts.